PURPOSE: The purpose of this study was to investigate the prognostic significance of the expression of EGFR and C-erbB-2 gene products by immunohistochemical analysis for curatively resected gastric adenocarcinoma. MATERIALS AND METHODS: Between January 1996 and December 2001, 739 patients with curatively resected gastric cancer patients underwent immunohistochemical staining for EGFR and C-erbB-2 proteins, and we retrospectively analyzed their correlation with the clinical outcome. RESULTS: The over expressions of EGFR and C-erbB-2 were 25.4% and 26.2%, respectively. The over expressions of EGFR was associated with the more poorly differentiated tumor (p=0.000) and with neuronal invasion (p=0.03). Over expression of C-erbB-2 was associated with less vascular invasion (p=0.001). Tumor depth or node metastasis was not related to the over expression of EGFR or C-erbB-2. The seven-year overall survival and relapse-free survival rates were 87.2% and 75.8%, respectively. Upon multivariate Cox regression analysis, the tumor stage, tumor size and patient age were important prognostic factors for overall survival, and tumor stage was the important factor for relapse-free survival. Over expressions of EGFR or c-erbB-2 were not significant prognostic factors. CONCLUSION: Immunohistochemical staining of EGFR and C-erbB-2 gene products were not independent prognostic factors for predicting the overall survival and the relapse-free survival in curatively resected gastric cancer.
PURPOSE: The purpose of this study was to investigate the prognostic significance of the expression of EGFR and C-erbB-2 gene products by immunohistochemical analysis for curatively resected gastric adenocarcinoma. MATERIALS AND METHODS: Between January 1996 and December 2001, 739 patients with curatively resected gastric cancerpatients underwent immunohistochemical staining for EGFR and C-erbB-2 proteins, and we retrospectively analyzed their correlation with the clinical outcome. RESULTS: The over expressions of EGFR and C-erbB-2 were 25.4% and 26.2%, respectively. The over expressions of EGFR was associated with the more poorly differentiated tumor (p=0.000) and with neuronal invasion (p=0.03). Over expression of C-erbB-2 was associated with less vascular invasion (p=0.001). Tumor depth or node metastasis was not related to the over expression of EGFR or C-erbB-2. The seven-year overall survival and relapse-free survival rates were 87.2% and 75.8%, respectively. Upon multivariate Cox regression analysis, the tumor stage, tumor size and patient age were important prognostic factors for overall survival, and tumor stage was the important factor for relapse-free survival. Over expressions of EGFR or c-erbB-2 were not significant prognostic factors. CONCLUSION: Immunohistochemical staining of EGFR and C-erbB-2 gene products were not independent prognostic factors for predicting the overall survival and the relapse-free survival in curatively resected gastric cancer.
Authors: E Santoro; M Carboni; M Catarci; M Carlini; F Carboni; G Zupi; A Vecchione; I D'Agnano; D Giannarelli; R Santoro; A Garofalo Journal: Hepatogastroenterology Date: 1997 May-Jun
Authors: R Kopp; M Ruge; E Rothbauer; C Cramer; H J Kraemling; B Wiebeck; F W Schildberg; A Pfeiffer Journal: Anticancer Res Date: 2002 Mar-Apr Impact factor: 2.480
Authors: I García; F Vizoso; A Andicoechea; P Raigoso; P Vérez; E Alexandre; J L García-Muñiz; M T Allende Journal: Int J Biol Markers Date: 2001 Jul-Sep Impact factor: 3.248
Authors: Roberto de Moraes Cordts Filho; Paulo Kassab; Laura Carolina Lopez Claro; Mabel Tatty de Medeiros Fracassi; Patrícia Colombo-Souza; Daniel Kenji Fukuhara; Fábio Rodrigues Thuler; Wilson Rodrigues de Freitas Junior; Elias Jirjoss Ilias; Carlos Alberto Malheiros Journal: ScientificWorldJournal Date: 2016-12-25
Authors: K Aydin; S K Okutur; M Bozkurt; I Turkmen; E Namal; K Pilanci; A Ozturk; Z Akcali; G Dogusoy; O G Demir Journal: Oncol Lett Date: 2013-11-06 Impact factor: 2.967